1. Home
  2. YALA vs OMER Comparison

YALA vs OMER Comparison

Compare YALA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YALA

Yalla Group Limited each representing one

HOLD

Current Price

$5.46

Market Cap

801.7M

Sector

Technology

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.27

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YALA
OMER
Founded
2016
1994
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
801.7M
772.8M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
YALA
OMER
Price
$5.46
$9.27
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
345.7K
2.3M
Earning Date
05-18-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.62
Revenue
N/A
$29,868,000.00
Revenue This Year
$16.40
N/A
Revenue Next Year
$7.13
$233.22
P/E Ratio
$8.76
$14.97
Revenue Growth
N/A
N/A
52 Week Low
$5.01
$3.34
52 Week High
$9.29
$17.65

Technical Indicators

Market Signals
Indicator
YALA
OMER
Relative Strength Index (RSI) 46.28 40.66
Support Level $5.23 $9.12
Resistance Level $7.27 $11.88
Average True Range (ATR) 0.18 0.92
MACD 0.08 0.04
Stochastic Oscillator 68.12 62.40

Price Performance

Historical Comparison
YALA
OMER

About YALA Yalla Group Limited each representing one

Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: